Scpharmaceuticals Soars 13.2% on MannKind Acquisition
Generated by AI AgentAinvest Pre-Market Radar
Monday, Aug 25, 2025 8:21 am ET1min read
MNKD--
SCPH--
On August 25, 2025, ScpharmaceuticalsSCPH-- surged 13.2% in pre-market trading, marking a significant rise in its stock price.
MannKind Corporation has announced its acquisition of Scpharmaceuticals for $303 million, a strategic move that expands MannKind's portfolio into the cardiorenal medicine sector. This acquisition brings FUROSCIX, a product with a remarkable 96% year-over-year growth, into MannKind's fold, which is expected to bolster the combined revenue of the two companies.
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet